anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a Cell Division Autoantigen (CDA) and includes polypeptide sequences, gene sequences encoding CDA, vectors containing those sequences, and host cells transformed to contain CDA sequences. The invention also provides antibodies directed against CDA. The invention also relates to the use of CDA as a therapeutic and diagnostic agent for the treatment of cell division associated diseases including cancer. In as aspect of the present invention, there is provided a nucleotide sequences encoding a cell division autoantigen (CDA) said sequence having the nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent, analogue, mutant or variant thereof. The invention specifically provides nucleotide and amino acid sequences including SEQ ID NO:1 and SEQ ID NO:2 respectively which encode for the CDA molecule. The invention also encompasses antisera and antibodies, including cytotoxic antibodies specific for the CDA polypeptide and/or CDA-derived polypeptides. The invention further encompasses immunogenic, prophlactic or therapeutic compositions, including vaccines, comprising one or more polypeptides. The invention additionally encompassed nucleotide sequences encoding said CDA polypeptide or CDA-derived polypeptides, functional equivalents, analogues, mutants, and variants thereof.
This is a phase I, double blind trial to evaluate the use of Aldehyde Dehydrogenase-Bright (ALDHbr) in ischemic cardiomyopathy patients. The study hypothesis is that transendocardial injections of autologous bone marrow cells in patients with end-stage ischemic heart disease is safe, can provide neovascularization, and can improve perfusion and myocardial contractility. The primary object of this study is to assess the safety of the ALDHbr cell injections. The efficacy will be based upon treadmill MVO2. A maximum of 60 patients will be enrolled in the study. At the end of 6 months, after the required testing has been completed, the patients will be told whether they were in the control group or not. The patients in the control group will be given the option to crossover and actually receive stem cell injection. At the time of crossover, which then becomes the baseline, patients will begin the follow-up with all testing including clinic visits for one year for a total of 18 months follow-up.
The invention discloses a dibutyltin coordination compound, a preparation method of the dibutyltin coordination compound and application of the dibutyltin coordination compound. The structural formula of the dibutyltin coordination compound is shown in the specification. The preparation method comprises the following steps of: adding 1mmol of 2-phenoxypropionic acid, 0.1-1.5mmol of potassium hydroxide, 0.5-1.5mmol of dibutyltin dichloride and 20-30ml of methanol into a container, stirring and refluxing for 6-7 hours at the room temperature, and then carrying out rotary evaporation to obtain a faint yellow solid; and recrystallizing by using dichloromethane-petroleum ether to obtain faint yellow transparent crystal, i.e. the dibutyltin coordination compound, wherein the volume ratio of the dichloromethane to the petroleum ether is 1:1-2:1. The application of the dibutyltin coordination compound lies in preparing medicaments for treating human ileocecum adenocarcinoma, human lung adenocarcinoma and human colon cancer. The organic dibutyltin coordination compound has the characteristics of high anti-cancer activity, good fat solubility, low cost, simple preparation method, and the like and provides a new approach for developing anti-cancer medicaments.
This study is an open-label investigation of the efficacy of injection of autologous adult bone marrow derived stem cells into the ovarian stroma of patients with premature ovarian failure. Sixty women with premature ovarian failure will be recruited in this study after a written informed consent. Diagnosis will be based mainly on history taking, physical examination and investigations. Laboratory investigations will include Serum follicle-stimulating hormone (FSH), serum estrogen measurement and serum AMH. The anterior pituitary secretes FSH and LH at high levels due to the dysfunction of the ovaries and consequent low estrogen levels. Typical FSH in POF patients is over 40 mlU/ml (post-menopausal range). Subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals. Human adult bone marrow derived stem cells will be transplanted by a gynecological surgeon through a standard surgical approach (transvaginal U/S guided approach). Subjects will be monitored frequently for a total of one year after adult bone marrow stem cells cell injection. For safety of participants, Bone Marrow Stem cells will be injected in one ovary only and the other ovary will be spared.
Increases in serum cholesterol and triglycerides can occur in patients receiving LORBRENA [see Adverse Reactions (6.1)]. Grade 3 or 4 elevations in total cholesterol occurred in 18% and Grade 3 or 4 elevations in triglycerides occurred in 19% of the 476 patients who received 100 mg LORBRENA once daily. The median time to onset was 15 days for both hypercholesterolemia and hypertriglyceridemia. Approximately 4% and 7% of patients required temporary discontinuation and 1% and 3% of patients required dose reduction of LORBRENA for elevations in cholesterol and in triglycerides in Study B7461001 and Study B7461006, respectively. Eighty-three percent of patients required initiation of lipid-lowering medications, with a median time to onset of start of such medications of 17 days.

Initiate or increase the dose of lipid-lowering agents in patients with hyperlipidemia. Monitor serum cholesterol and triglycerides before initiating LORBRENA, 1 and 2 months after initiating LORBRENA, and periodically thereafter. Withhold and resume at the same dose for the first occurrence; resume at the same or a reduced dose of LORBRENA for recurrence based on severity [see Dosage and Administration (2.3)].
PURPOSE:To inactivate a kinin compound and to prevent the development of pain-producing action of kinin compound in living body, by decomposing a kinin compound with laser beam radiation. CONSTITUTION:A kinin compound (e.g. bradykinin, lysyl bradykinin, etc.) is decomposed and inactivated with laser bean radiation. Although a kinin compound effectively functions mainly as a vasodilator in living body, it is produced abundantly in the blood vessel near the stimulated site when a part of a living body is stimulated and functions also as a pain-producing substance (PPS) acting to the terminal of a neurocyte to produce pain. The peptide bond of the kinin compound is broken by the irradiation of laser beam and the kinin compound is decomposed in a living body to decomposition products such as oligopeptide or amino acid residue. Accordingly, it is inactivated and does not exist as PPS producing pain in a living body. The wavelength of the laser beam is usually about 0.19-4.0mum.
Background: Upper-face feminization is a frequently executed procedure in sexual reassignment surgery, owing to its ability to influence gender identity through adjustments to the hairline, forehead, and peri-orbital area. The procedure includes reducing the hairline, lifting the brows, shaving the orbital region, and applying specific techniques to reduce the frontal bone. This research aims to assess the outcomes, results, and potential complications associated with this surgery among transgender patients. Material and Method: Retrospective review of medical records of 20 patients who attended for facial feminization surgery of the upper face between June 2022 and June 2023, analyzing the previously performed procedures, complications and revision surgery outcomes, and first-time procedures. A literature review was performed for similar studies. Results: 20 patients were included in the study. Among the cohort treated elsewhere (n = 11), the primary complaint was insufficient browbone reduction and anterior frontal sinus table setback. They underwent poorly performed Type 1 reduction when full forehead reconstruction (Type 3/4) was indicated (n = 3), or no reduction was performed during hairline advancement (n = 4). Type 3 forehead reduction with orbital shaving and hairline advancement with simultaneous temporal browlift was most commonly performed in both revision and first-time surgical upper face feminization (n = 15) (75%). Type 1 osteoplasty was performed in four patients (10%), one Type 3 revision surgery was performed after insufficient Type 3 reduction, and one case of shock-induced alopecia was reported, treated with PRP/peptides and a FUE hair graft. Conclusions: The author's preferred technique, 'whole-in-one' upper face feminization by modified bi-coronal incision with frontal trichophytic hyper-beveled incision, provides sufficient insight into the frontal bone and orbital region, the desired forehead osteoplasty and the most efficient insight into the temporal area, enabling safe dissection between fasciae, ligamentous adhesion removal, and periosteal attachment, providing full soft and hard tissue feminization. Nevertheless, feminization procedures should be meticulously planned, and all concerning issues should be addressed during the first surgery in order to prevent revisions, complications, and patient dissatisfaction.
<P>PROBLEM TO BE SOLVED: To a bleaching ingredient that has an excellent melanogenesis inhibitory action and excellent hypochromic and bleaching effect on pigmentation/stain/freckle/liver spot, etc., after sunburn.  <P>SOLUTION: The bleaching ingredient comprises an extract of one or more kinds of plants selected from the group consisting of Pleomele angustifolia (Roxb.) N. E. Br. of a plant of the family Liliaceae, Oxalis corymbosa DC. of a plant of the family Oxalidaceae and Sonchus oleraceus L. of a plant of the family Compositae.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PCT No. PCT/US95/06473 Sec. 371 Date Mar. 22, 1996 Sec. 102(e) Date Mar. 22, 1996 PCT Filed May 23, 1995 PCT Pub. No. WO95/31980 PCT Pub. Date Nov. 30, 1995A method is provided to treat and/or prevent striae distensae lesions by topically applying to the skin affected with the lesions an effective amount of a treatment composition containing an alpha hydroxy acid, such as glycolic acid, preferably by daily application in a pharmaceutically acceptable vehicle, such as a cream base, at a concentration of from 2 to 30 percent by weight. When applied during the striae rubrae stage, the alpha hydroxy acid may be effective to prevent the formation of striae albae lesions, and when applied in either stage, the alpha hydroxy acid may be effective to reduce the width and depth of the lesions, and improve the color of striae rubrae.
A 4-week LAA intervention included low-level laser acupuncture and auricular acupressure. Six acupuncture points were selected, and three auricular points. Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. After five days, the seed was removed, and a new seed was taped on the other ear.
Alzheimer's disease (AD) and depression are inflammatory pathologies, leading to increased inflammatory response and neurotoxicity. Therefore, this study aimed to evaluate the effect of the treatment with fluoxetine and/or galantamine and/or donepezil on the levels of proinflammatory and anti-inflammatory cytokines in a mixed animal model of depression and dementia. Adult male Wistar rats underwent chronic mild stress (CMS) protocol for 40 days and were subjected to stereotaxic surgery for intra-hippocampal administration of amyloid-beta (Aꞵ) peptide or artificial cerebrospinal fluid (ACSF) to mimic the dementia animal model. On the 42nd day, animals were treated with water, galantamine, donepezil, and/or fluoxetine, orally for 17 days. On the 57th and 58th days, the Splash and Y-maze tests for behavior analysis were performed. The frontal cortex and hippocampus were used to analyze the tumor necrosis factor alfa (TNF-α), interleukin 1 beta (IL-1ꞵ), IL-6, and IL-10 levels. The results of this study show that animals subjected to CMS and administration of Aꞵ had anhedonia, cognitive impairment, increased TNF-α and IL-1ꞵ levels in the frontal cortex, and reduced IL-10 levels in the hippocampus. All treatment groups were able to reverse the cognitive impairment. Only donepezil did not decrease the TNF-α levels in the hippocampus. Fluoxetine + galantamine and fluoxetine + donepezil reversed the anhedonia. Fluoxetine reversed the anhedonia and IL-1ꞵ levels in the frontal cortex. In addition, fluoxetine + donepezil reversed the reduction of IL-10 levels in the hippocampus. The results indicate a pathophysiological interaction between AD and depression, and the association of medications in the future may be a possible therapeutic strategy to reduce inflammation, especially the fluoxetine-associated treatments.
Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and Genome-wide association studies (GWAS) risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation, and proportion analysis, signifies ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high systolic blood pressure in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population-specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic-specific variation can help in determining regional risk drivers for stroke. Unique ethnic-specific risk variants and their distinct patterns of linkage disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population- and comorbidity-specific risk variants might help in defining the threshold for risk, and aid in developing population-specific prevention strategies for stroke.
BP-MAP is a cluster randomized controlled trial (RCT) designed to compare the effectiveness of BP lowering from a clinic-based quality improvement program with Full Support (dedicated practice facilitation) vs. a Self-Guided version of the program. The American Medical Association (AMA) developed the framework for the interventions. The trial will be conducted within the National Patient-Centered Clinical Research Network (PCORnet) that enables distributed querying of electronic health record data in a common data model. The primary outcome will be change in clinic-level blood pressure (BP) control at 6 months. Secondary outcomes will include other blood pressure (BP) control metrics, other time points (12 and 18 months), and process measures such as BP measurement accuracy, medication intensification, and average systolic blood pressure (SBP) reduction after a medication intensification, and repeat visit within 4 weeks after a visit with elevated BP. The investigators hypothesize clinics randomized to the Full Support version will achieve a larger increase from baseline in the proportion of their hypertensive patients with controlled BP at 6 months as compared to clinics randomized to the Self-Guided version, and also as compared with usual care. The investigators will also conduct non-randomized comparisons of BP control in the Full Support and Self-Guided intervention arms to BP control in non-participating "Usual Care" institutions in PCORnet. This study was submitted to the IRB at UCSF, determined to be quality improvement and exempt from further review.
Patients in the placebo arms will receive IV placebo on the same schedule for 12 weeks. All patients are eligible to receive Rescue conventional IV iron if criteria are met and the patient's principal physician agrees.
The invention provides an ophthalmic solution with a flavoring agent as a dosing indicator and a method for indicating dosage of an ophthalmic solution. To indicate dosage, a flavoring agent is added to an ophthalmic solution in an amount correlated to the dosage of the ophthalmic solution to be used. The flavoring agent can be a sweet flavoring agent (sweetener), or combinations of a sweetener with a sour flavoring agent or a bitter flavoring agent or mixtures thereof. The flavoring agent may also be natural flavors, natural fruit flavors, artificial flavors, artificial fruit flavors, flavor enhancers and mixtures thereof, which may be combined with a sweetener, a sour flavoring agent, a bitter flavoring agent, and mixtures thereof. The invention may be utilized as a contact lens solution, an eye drop formulation, and a pharmaceutical composition containing at least one active pharmaceutical ingredient for the treatment of eye diseases. The invention also provides to a method of administering a dose of an ophthalmic solution to the person's eye.
FIELD: chemistry; biochemistry. ^ SUBSTANCE: Lactobacillus fermentum TS3-06 strain is isolated from sour milk broth used in production of curdled milk. The obtained Lactobacillus fermentum TS3-06 strain is deposited in the collection of microorganisms of the department of microbiology of the Faculty of Biology of M.V. Lomonosov Moscow State University under registration number 498 CM MSU. The strain is used to make bacterial preparations and making sour milk broth as a food product for medical and preventive purposes. ^ EFFECT: higher growth rate, high resistance to extreme effects such as low acidity, bile content, resistance to antibiotics. ^ 2 dwg, 3 tbl, 4 ex
Sertraline is indicated for the treatment of social anxiety disorder, also known as social phobia in adults.

The efficacy of sertraline in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). 

Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress.

The efficacy of sertraline in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY).
Session 2 for participants randomized to group MG will focus on gratitude. Participants will be taught to reflect on things, events, and people which they are grateful for via a gratitude meditation. Couples will share their experiences of practicing gratitude. The instructor will remind the couple of ground rules prior to the emotional disclosure exercise and facilitate if necessary during the sharing. Each member of the couple will take turn in sharing with and listening to their partner. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
Neuroimaging studies have demonstrated the association of the cognitive control network (CCN) with the maintenance of chronic pain. However, whether and how dorsolateral prefrontal cortex (DLPFC), a key region within the CCN, is altered in menstrual pain is unclear. In this study, we aimed to investigate alterations in the DLPFC functional connectivity network in patients with primary dysmenorrhea (PDM). The study comprised 41 PDM patients and 39 matched healthy controls (HCs), all of whom underwent a resting-state functional MRI scan during the menstrual stage. All participants were instructed to complete the clinical assessment before the MRI scan. We used the DLPFC as the seed in resting-state functional connectivity (rsFC) analysis to investigate the difference between PDM patients and HCs. Compared to HCs, PDM patients showed increased right DLPFC rsFC at the bilateral lingual gyrus, dorsal anterior cingulate cortex (dACC), and middle cingulate cortex, and decreased left DLPFC rsFC at the right orbital frontal cortex. In addition, increased right DLPFC-bilateral dACC connectivity mediated the association between disease duration and the self-rating anxiety scale (SAS) scores in PDM patients. We confirmed that the DLPFC-dACC rsFC was associated with higher SAS scores, which could mediate the association between disease duration and anxiety symptoms in patients with PDM. Our findings provide central pathological evidence for an abnormal rsFC of the CCN in PDM patients, which may contribute to a better understanding of the neuropathophysiological mechanisms underlying PDM.